Speakers

Miranda works as Head of CMC at Hybridize Therapeutics. As owner of M3 Pharma Consultancy she also supports development activities of other companies, on a parttime consultancy basis. Hybridize Therapeutics is an innovative Dutch biotech company that was founded in 2019 as a spin-out from Leiden University Medical Center. The company’s main focus is the development of RNA therapies for untreated kidney diseases.

Miranda has more than 18 years of experience in the pharmaceutical industry. She worked for large “big pharma” companies as well as for small and virtual start-ups, both as an employee and as a consultant. She enjoys pioneering and working on complex projects in an international and multidisciplinary environment.

Miranda has acted as CMC leader of multiple early to late stage development projects. Over the years she collaborated with a wide range of academic and industrial partners for CMC, drug delivery and nonclinical related activities. Being responsible for delivering project objectives at high quality and within agreed budget and timelines, finding creative solutions for challenges that pop up along the way and being able to collaborate with many dedicated internal and external colleagues is what gives her energy and drives her every day.

Presentation Title: Creating the Optimal Environment for Sponsor and Supplier Partnerships to Thrive & Prosper

Abstract: Many small pharma/biotech companies outsource the entire CMC development and manufacturing activities to CDMO’s and often work with CMC Consultants. This presentation will discuss experiences, challenges and pitfalls, specifically focused on oligonucleotide development in the orphan disease space.

View company profile